Exhibit 99.1 Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates – Expansion of Phase 1 CALiPSO-1 trial of CNTY-101 in autoimmune disease to include dif use cutaneous systemic sclerosis and idiopathic inflammatory myopathy – – Overall response rate (ORR) of 83% observed at CNTY-101 Dose Level 3B alongside a favorable safety profile in patients with r/r B-cell lymphomas in Phase 1 ELiPSE-1 study – – CNTY-101 shows persistence upon repeated cell dosing at Dose Level ...